Compare NCPL & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCPL | NXTS |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | Israel |
| Employees | 20 | 9 |
| Industry | Investment Managers | Agricultural Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.3M |
| IPO Year | N/A | N/A |
| Metric | NCPL | NXTS |
|---|---|---|
| Price | $0.42 | $4.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 159.4K | 19.7K |
| Earning Date | 03-19-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.55 |
| 52 Week High | $8.75 | $6.21 |
| Indicator | NCPL | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 59.10 |
| Support Level | $0.36 | $3.92 |
| Resistance Level | $0.47 | $5.31 |
| Average True Range (ATR) | 0.03 | 0.62 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 89.29 | 36.26 |
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.